Im SA - Search Results

1

HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.

Tan RSYC, Ong WS, Lee KH, Lim AH, Park S, Park YH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Ryu HS, Han W, Tan VKM, Wong FY, Im SA, Tan PH, Chan JY, Yap YS. Tan RSYC, et al. Among authors: im sa. BMC Med. 2022 Mar 17;20(1):105. doi: 10.1186/s12916-022-02284-6. BMC Med. 2022. PMID: 35296300 Free PMC article.

2

Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.

Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK, Park HS. Im SA, et al. Among authors: im yh. Oncol Rep. 2005 Aug;14(2):481-7. Oncol Rep. 2005. PMID: 16012734 Clinical Trial.

3

Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type.

Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, Chang KH, Kim NK. Kim TM, et al. Among authors: im sa. Blood. 2005 Dec 1;106(12):3785-90. doi: 10.1182/blood-2005-05-2056. Epub 2005 Aug 18. Blood. 2005. PMID: 16109779 Free article.

4

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.

Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ. Han SW, et al. Among authors: im sa. Clin Cancer Res. 2006 Apr 15;12(8):2538-44. doi: 10.1158/1078-0432.CCR-05-2845. Clin Cancer Res. 2006. PMID: 16638863

5

Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.

Lee KH, Han SW, Hwang PG, Oh DY, Kim DW, Chung DH, Im SA, Kim TY, Heo DS, Bang YJ. Lee KH, et al. Among authors: im sa. Jpn J Clin Oncol. 2006 Jun;36(6):344-50. doi: 10.1093/jjco/hyl039. Jpn J Clin Oncol. 2006. PMID: 16818479

6

High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.

Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, Kim TY, Kim YW, Bang YJ, Heo DS. Lee KH, et al. Among authors: im sa. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4232-6. doi: 10.1158/1078-0432.CCR-05-2710. Clin Cancer Res. 2006. PMID: 16857796

7

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ. Han SW, et al. Among authors: im sa. Lung Cancer. 2006 Nov;54(2):201-7. doi: 10.1016/j.lungcan.2006.07.007. Epub 2006 Sep 7. Lung Cancer. 2006. PMID: 16956694

8

Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.

Han SW, Jeon YK, Lee KH, Keam B, Hwang PG, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY. Han SW, et al. Among authors: im sa. Pharmacogenet Genomics. 2007 May;17(5):313-9. doi: 10.1097/FPC.0b013e328011abc0. Pharmacogenet Genomics. 2007. PMID: 17429313

9

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Lee KH, et al. Among authors: im sa. BMC Cancer. 2007 Apr 12;7:63. doi: 10.1186/1471-2407-7-63. BMC Cancer. 2007. PMID: 17430582 Free PMC article.

10

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.

Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Keam B, et al. Among authors: im sa. BMC Cancer. 2007 Nov 1;7:203. doi: 10.1186/1471-2407-7-203. BMC Cancer. 2007. PMID: 17976237 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

659 results

Search Page